Skip to content

BMC neurology

ISSN 1471-2377

4 papers in the library · 7 citations · publishing 2024-2025

Papers

Study protocol for the MIND-PD study: a randomized controlled trial to investigate clinical and biological effects of mindfulness-based cognitive therapy in people with Parkinson's disease.

BMC neurology June 25, 2024 Anouk Van der Heide, Franziska Goltz, Nienke M De Vries et al. 5 citations

Mindfulness-Based Cognitive Therapy (MBCT) may reduce anxiety and depression in people with Parkinson's disease (PD), who are highly sensitive to stress. A randomized controlled trial will compare 8 weeks of MBCT to usual care in 124 PD patients with mild-to-moderate anxiety and depression, disease duration ≤10 years, and no prior mindfulness experience. Participants are followed for 12 months, with clinical, biochemical, and MRI assessments at baseline, 2 months, and 12 months. The primary outcome is change in Hospital Anxiety and Depression Scale score at 2 months. The trial also explores effects on motor symptoms, stress markers, and biomarkers of PD progression.

Development of a nomogram for predicting the outcome in patients with prolonged disorders of consciousness based on the multimodal evaluative information.

BMC neurology April 23, 2025 Juanjuan Fu, Yongli Wu, Hui Feng et al. 1 citation

A nomogram prediction model integrating four factors—CRS-R score, brainstem auditory evoked potential (BAEP) grading, N60 classification of somatosensory evoked potentials, and estradiol level—accurately forecasts whether patients with prolonged disorders of consciousness (PDOC) after brain injury will show improved consciousness at six months. In a training cohort of 121 patients, 52.1% improved; in a validation cohort of 49 patients, 51% improved. The model achieved an area under the curve of 0.919 in the training set and 0.888 in the validation set, indicating strong discriminative ability. Calibration and decision curve analyses confirmed the model's accuracy and clinical net benefit.

Time moving 100-fold slower: time distortion as a diagnostic clue in anti-NMDA receptor encephalitis.

BMC neurology February 24, 2025 Risa Hirata, Hisashi Wada, Kazunori Yamamoto et al. 1 citation

In the early stages of anti-NMDA receptor encephalitis, psychiatric symptoms dominate, making it hard to distinguish from primary psychiatric disorders. Two detailed cases show that pronounced time distortion—specifically the perception of time moving slowly—can be a key early symptom. A middle-aged man experienced time moving 100 times slower, persisting over a year after other symptoms resolved. A young woman reported time moving two to three times slower. Because patients may not spontaneously mention time distortion, actively asking about it during evaluation could aid early diagnosis and treatment of this potentially lethal condition.

Ketamine for acute management of refractory stiff person syndrome: a case report.

BMC neurology April 9, 2025 Evan Eggiman, William Kerr, Brandon Spivey et al.

A 22-year-old man with Stiff Person Syndrome, an autoimmune neurological disorder causing progressive muscle rigidity and painful spasms, experienced acute symptom exacerbation unrelieved by high-dose benzodiazepines, baclofen, and intravenous methocarbamol. Treatment with intravenous ketamine produced rapid and significant symptom resolution. Although recurrent flares required repeated ketamine administration, it remained consistently effective when standard treatments failed. The patient's care was complicated by anxiety, hypoxia, and venous thromboembolism. Ketamine's antagonism of NMDA receptors and enhancement of GABAergic signaling may underlie its benefit, suggesting it as a potential second-line treatment for refractory SPS exacerbations.